

NeuroMetrix' Quell Device Makes Second Appearance at American Society of Regional Anesthesia's Annual Pain Medicine Meeting

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American Society for Regional Anesthesia's Annual Pain Medicine Meeting to be held November 17-19 in San Diego, CA.

"Since we introduced Quell to the ASRA community a year ago, we have made significant progress against our healthcare professional strategy," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "In the past 12 months, NeuroMetrix has captured over 2,000,000 hours of user data in the Quell Health Cloud, published results in the [Journal of Pain Research](#), and initiated several clinical evaluations that we are excited to discuss with this year's meeting attendees."

About the American Society for Regional Anesthesia (ASRA) and its Annual Pain Medicine Meeting

Originally founded in 1923, ASRA was reborn in 1975 and is the largest subspecialty medical society in anesthesiology. It has approximately 4,000 members, including physicians and scientists, and a rich international distribution. ASRA's Annual Pain Medicine Meeting will bring together over 1,000 clinical practitioners and researchers in the area of pain medicine. For more information, visit www.asra.com.

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161116005225/en/>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media